Trial Profile

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC 4881 (Primary)
Indications Familial adenomatous polyposis
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Acronyms TUPELO
Sponsors Recursion Pharmaceuticals

05 Aug 2026 According to a Genentech media release, discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26.
05 Aug 2026 According to a Genentech media release, trial is now enrolling patients ages 18 and older, as well as a cohort with an alternative dosing schedule.
05 Aug 2026 According to a Genentech media release, additional phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting (CGA-IGC) in Nov 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com